Download the Visual
In-vivo CD19 is crowded early, and only one program has reached Phase 2
In-vivo CD19 cell therapy is crowded and early: of 91 programs on Sleuth’s September 2026 map, only one has reached Phase 2, an investigator-initiated oncology study at the Chinese PLA General Hospital that pairs CD19 with CD20. The programs come from 71 companies, academic institutions and hospitals, and roughly half of the developers are still preclinical. Big Pharma has already bought in, through five acquisitions of in-vivo developers announced between March 2025 and February 2026.
The map sorts programs by treatment area (oncology, autoimmunity or both), highest development stage and whether each targets CD19 alone or with a second antigen. It is the CD19 slice of Sleuth’s Q3 2026 in-vivo cell therapy report.
CD19 plus BCMA leads multi-target designs, but a second target has to earn its place
Most entries on the map target CD19 alone; T-cell delivery targets such as CD3, CD4, CD7 and CD8 are not counted as partners. Among combinations, BCMA is by far the most common partner, ahead of CD20, with single entries pairing CD19 with CD22, BAFF-R or PD-1 and one triple adding BCMA and CD70.
CD19 alone is a B-cell reset. Adding BCMA reaches long-lived plasma cells that can escape CD19-only treatment, which matters in both oncology and autoimmune disease. But broader depletion has to justify itself: if CD19 alone delivers durable remission with a cleaner safety profile, a second target may add only incremental value.
The delivery platform also matters. Whether a program uses linear mRNA in targeted lipid nanoparticles (tLNPs), circular RNA in tLNPs or targeted lentiviral vectors largely determines how long the CAR is expressed and whether the therapy can be redosed.
Oncology and autoimmune disease pull development in different directions
Pursuing oncology and autoimmune disease together is increasingly popular given the larger addressable market, but the two have different development priorities. Refractory cancer optimizes for depth and duration of depletion, because the disease is lethal and the goal is durable tumor control. Moving in-vivo approaches into earlier-line autoimmune disease means competing with treatments that can manage the disease for years, which makes safety, outpatient feasibility and controllability central to the commercial case.
The stage data reflect that gap. Autoimmune-only programs have reached Phase 1 at most, with AbbVie, Lilly, Circunited Biopharma, MagicRNA and Sichuan University furthest along, while the only Phase 2 program is in oncology. Eight Chinese hospitals and universities run programs at Phase 1 or later.
The long-term autoimmune market is potentially large, but the first step is showing durable benefit in severe, refractory patients to justify earlier-line use.
Big Pharma bought in early, and its I&I buyers are aiming at autoimmune disease
Big Pharma entered early through acquisitions, listed here by announcement date and headline value:
- AstraZeneca and EsoBiotec: up to $1 billion, March 2025
- AbbVie and Capstan: up to $2.1 billion, June 2025
- Gilead’s Kite and Interius: $350 million, August 2025
- BMS and Orbital Therapeutics: $1.5 billion, October 2025
- Lilly and Orna: up to $2.4 billion, February 2026
AstraZeneca, whose EsoBiotec deal was for an in-vivo platform, does not appear on the CD19 map.
BMS and Gilead bring deep cell therapy roots, while AbbVie and Lilly built on immunology and inflammation (I&I) expertise and acquired programs specifically to pursue autoimmune disease, where both now have Phase 1 programs. For them, in-vivo delivery could reduce reliance on the bespoke manufacturing that defined the first generation of cell therapy.
If these therapies reach broader autoimmune populations, I&I development expertise, key opinion leader relationships and delivery IP could matter more than cell therapy heritage in deciding who wins.
Programs and stages are as of September 2026, with each developer placed at its highest stage by treatment area (IND-enabling shown as preclinical; Phase 1 and 1/2 combined). Partnered programs show the lead company, and the map is not exhaustive. Deal values are headline figures at announcement.
Frequently asked questions about in-vivo CD19 cell therapy
How many in-vivo CD19 programs are in development?
Sleuth mapped 91 in-vivo CD19 cell therapy programs across 71 companies, academic institutions and hospitals as of September 2026, and roughly half of the developers are still preclinical.
Which in-vivo CD19 program is most advanced?
As of September 2026, the only Phase 2 program on Sleuth’s map is an investigator-initiated oncology study at the Chinese PLA General Hospital combining CD19 with CD20. In autoimmune disease, the most advanced programs are in Phase 1, including those of AbbVie, Lilly and MagicRNA.
Which big pharma companies have bought in-vivo CAR-T companies?
AstraZeneca (EsoBiotec), AbbVie (Capstan), Gilead’s Kite (Interius), BMS (Orbital) and Lilly (Orna) announced acquisitions between March 2025 and February 2026, worth $350 million to $2.4 billion each.
